In a Phase III trial, Proxalutamide reduced mortality and expedited recovery of hospitalised COVID-19 patients in Brazil.
List view / Grid view
The trial will evaluate the safety, tolerability and immunogenicity of Ultimovacs’ prostate cancer-specific therapeutic TET-based vaccine.
A new oil-based oral formulation of prostate cancer drug abiraterone acetate could enable a smaller dose of the drug to be effective and reduce possible side effects, a study has shown.
The EMA has suggested that the safety information be updated for HRT, to reflect a higher risk of breast cancer and recommends new measures for the handling of leuprorelin depot medicines.
European Pharmaceutical Review investigates five of the latest cancer drug approvals and clinical trial results.
After a review of cyproterone, the EMA has recommended that the drug only be prescribed once other treatment options have failed, due to an increased meningioma risk.
The EMA’s human medicines committee (CHMP) recommended fifteen medicines for various approvals at its January 2020 meeting; with ten drugs receiving marketing authorisation recommendations and five receiving positive opinions for specific treatments.
A Phase III study of oral relugolix has met its primary efficacy endpoint in men with advanced prostate cancer, supporting a New Drug Application submission to the FDA.
The FDA has given the designation to niraparib for the treatment of gene-mutated castration-resistant prostate cancer.
Sanofi has won the latest appeal for the patent of its top oncology product, Jevtana (cabazitaxel).
Amgen and Astellas Pharma US have agreed to pay a total of $124.75 million to settle allegations that they paid kickbacks to Medicare copays for their own medications.
A Phase III clinical trial has shown that metastatic prostate cancer improved through the use of a combination therapy with enzalutamide...
Erleada (apalutamide) has been approved for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease
A clinical trial could be the world's first to look at personalised medicine in prostate cancer, with patients taking a therapy based on their DNA markers...